TECH

Bio-Techne Corp

TECH, USA

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

https://www.bio-techne.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TECH
stock
TECH

PHX Energy Services: Small-Cap Oilfield Tech Stock Tests Investor Nerves After Recent Pullback AD HOC NEWS

Read more →
TECH
stock
TECH

Quantum Computing Stocks: Separating Hype From Reality in 2026 The Motley Fool

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$69.1667

Analyst Picks

Strong Buy

7

Buy

3

Hold

5

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

133.22

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

5.46

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

1.94 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

1.51 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Low

7.75 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.29

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 93.31% of the total shares of Bio-Techne Corp

1.

Vanguard Group Inc

(11.8537%)

since

2025/06/30

2.

BlackRock Inc

(7.8247%)

since

2025/06/30

3.

T. Rowe Price Associates, Inc.

(5.6882%)

since

2025/06/30

4.

Morgan Stanley - Brokerage Accounts

(4.2295%)

since

2025/06/30

5.

State Street Corp

(3.7664%)

since

2025/06/30

6.

US Small-Cap Growth II Equity Comp

(3.6471%)

since

2025/06/30

7.

Vanguard Total Stock Mkt Idx Inv

(3.1695%)

since

2025/07/31

8.

T. Rowe Price New Horizons

(3.1531%)

since

2025/07/31

9.

Geode Capital Management, LLC

(2.6117%)

since

2025/06/30

10.

Eaton Vance Atlanta Capital SMID-Cap I

(2.5581%)

since

2025/07/31

11.

Vanguard 500 Index Investor

(2.4948%)

since

2025/07/31

12.

Vanguard Small Cap Index

(2.4464%)

since

2025/07/31

13.

Amvescap Plc.

(2.3547%)

since

2025/06/30

14.

Ameriprise Financial Inc

(2.2096%)

since

2025/06/30

15.

Select Equity Group LP

(1.8769%)

since

2025/06/30

16.

BAMCO Inc

(1.7969%)

since

2025/06/30

17.

Invesco S&P 500® Equal Weight ETF

(1.7646%)

since

2025/08/29

18.

DF Dent & Co Inc

(1.7517%)

since

2025/06/30

19.

Mairs & Power Inc

(1.7463%)

since

2025/06/30

20.

Champlain Investment Partners, LLC

(1.7137%)

since

2025/06/30

21.

Mackenzie Investments

(1.6838%)

since

2025/06/30

22.

Champlain Mid Cap Fund, LLC

(1.6516%)

since

2025/08/31

23.

Neuberger Berman Group LLC

(1.6072%)

since

2025/06/30

24.

Citadel Advisors Llc

(1.5885%)

since

2025/06/30

25.

Sumitomo Mitsui Trust Group Inc

(1.5106%)

since

2025/06/30

26.

RGM Capital LLC

(1.4144%)

since

2025/06/30

27.

Vanguard Small Cap Growth Index Inv

(1.378%)

since

2025/07/31

28.

Fidelity 500 Index

(1.2775%)

since

2025/07/31

29.

Bank of New York Mellon Corp

(1.2363%)

since

2025/06/30

30.

SPDR® S&P 500® ETF

(1.2277%)

since

2025/08/31

31.

NORGES BANK

(1.2275%)

since

2025/06/30

32.

iShares Core S&P 500 ETF

(1.2205%)

since

2025/08/31

33.

T. Rowe Price New Horizons Tr-A

(1.1803%)

since

2025/06/30

34.

Baron Growth Retail

(0.9965%)

since

2025/06/30

35.

Baron Small Cap Growth Strategy

(0.9965%)

since

2025/06/30

36.

Neuberger Berman Genesis Inv

(0.9782%)

since

2025/06/30

37.

Mairs & Power Multi Cap

(0.896%)

since

2025/06/30

38.

Mairs & Power Growth

(0.896%)

since

2025/06/30

39.

Macquarie Mid Cap Growth A

(0.8424%)

since

2025/07/31

40.

Macquarie US Mid Cap Growth Equity

(0.8424%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.4355

Latest Release

Date

2025-09-30

EPS Actual

0.42

EPS Estimate

0.43

EPS Difference

-0.01

Surprise Percent

-2.3256%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(7)
Dividend
Decent Dividend Payer(3.5)
Economic Moat
Wide Moat Company(7.8)
GARP
Fair GARP(4)
Growth
Weak Growth Prospect(2.5)
Momentum
Strong Momentum(7)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(7)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.